Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.55 |
| ▸ | NPC1 | O15118 | 11/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854856 | 1.00 | RAB9A (0.55) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL27211127 | 0.88 | RAB9A (0.54) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL2323680 | 0.87 | RAB9A (0.52) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL4074315 | 0.83 | FDPS (0.46) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL14496947 | 0.83 | RAB9A (0.55) | RAB9ANPC1TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5543100 | 0.81 | RAB9A (0.54) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL9891790 | 0.81 | RAB9A (0.68) | RAB9ANPC1MEN1KMT2ATP53 | |
| SCHEMBL356367 | 0.80 | PTK2 (0.62) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL29883001 | 0.80 | PTK2 (0.62) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL5256669 | 0.80 | RAB9A (0.57) | RAB9ANPC1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230027929-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-114901280-A | MrgprX2 antagonists and uses thereof | 德米拉公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-5019578-A | β-adrenergic agonists | MERCK & CO., INC. (US) | 1991-05-28 | — | — | US | disclosed |
| EP-0318092-A2 | Novel beta-adrenergic agonists | MERCK & CO. INC. (US) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | RAB9A 3331/4885NPC1 4872/4885TSHR 1756/4885 |
| US-20230027929-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | RAB9A 1911/4885NPC1 573/4885TSHR 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.